Laniyati Hamijoyo, Laniyati
Departemen Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Padjadjaran Rumah Sakit Umum Pusat Hasan Sadikin Bandung

Published : 53 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search
Journal : The Indonesian Biomedical Journal

N-Acetyltransferase 2 (NAT2) Acetylator Status among Systemic Lupus Erythematosus Patients from A Tuberculosis Endemic Area in Bandung, Indonesia Laniyati Hamijoyo; Sasfia Candrianita; Ika Agus Rini; Endang Sutedja; Budi Setiabudiawan; Edhyana Sahiratmadja
The Indonesian Biomedical Journal Vol 11, No 2 (2019)
Publisher : The Prodia Education and Research Institute (PERI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.18585/inabj.v11i2.553

Abstract

BACKGROUND: Systemic lupus erythematosus (SLE) patients living in Indonesia are prone to tuberculosis (TB) infection, since this country ranks second globally for TB prevalence. Isoniazid, an anti-tuberculosis (TB) drug, is metabolized by enzyme N-acetyltransferase 2 (NAT2) that is encoded by NAT2 gene. NAT2 haplotype, referring as acetylator status, may predispose as genetic factor in SLE development or complicate SLE therapy. This study explored the NAT2 haplotypes and acetylator status among SLE patients living in a TB endemic area.METHODS: Genomic DNA of 260 registered SLE patients at The Rheumatology Clinic of Dr. Hasan Sadikin General Hospital, Bandung, Indonesia were isolated. NAT2 gene was amplified and sequenced, then NAT2 haplotypes and the acetylator status among SLE patients with or without TB history were determined and presented.RESULTS: Most of SLE patients registered were female (n=250; 96.2%). The median age of patients when SLE was diagnosed for the first time was 27 years old (8-69 years), with organ involvement predominantly in musculoskeletal (80.8%) and mucocutaneous (73.1%). TB history, mostly pulmonary TB, was present in 23.1% of SLE patients of whom TB was diagnosed before SLE (10.4%) or after SLE (10.7%) or both before and after SLE (2%). The acetylator status was mostly intermediate (61.5%) with the NAT2*4/*6B was the most prevalent haplotype (25.8%).CONCLUSION: There is a high number of intermediate and low acetylator status among SLE patients. Since these SLE patients live in TB endemic area, the NAT2 acetylator status determination among SLE patients before starting TB therapy may have clinical benefit to decrease a possible drug induced liver injury, and this warrants further study.KEYWORDS: NAT2, acetylator, systemic lupus erythematosus, tuberculosis
B Cell-Activating Factor (BAFF) and Ubiquitin Enzyme A20 as Functional Proteins in Targeted Therapy on Patients with Systemic Lupus Erythematosus Fajar, Desi Reski; Rostinawati, Tina; Hamijoyo, Laniyati; Barliana, Melisa Intan
The Indonesian Biomedical Journal Vol 16, No 5 (2024)
Publisher : The Prodia Education and Research Institute (PERI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.18585/inabj.v16i5.3161

Abstract

BACKGROUND: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by inflammation. The pathogenesis of SLE involves key proteins, including B cell-activating factor (BAFF) and the ubiquitin enzyme A20, both serving as negative regulators of inflammation and contributing to B cell homeostasis. In this review, focused on interventions directed at BAFF and the A20 enzyme, utilizing monoclonal antibodies either independently or in conjunction with conventional therapy for SLE patients.METHODS: A literature search was conducted on the PubMed platform by combining various terms, including "B-cells activating factor", "TNFAIP3 protein (human)", "therapeutics" or "drug therapy", and "lupus erythematosus, systemic" (limited to the last 10 years). From total of 104 articles discovered in thr search, the total number of articles collected after being filtered was 27 articles.RESULTS: Clinical development and evaluation have been conducted regarding the use of appropriate therapy for SLE patients. Selective BAFF inhibitor has been tested in clinical trials as a blocking agent in BAFF receptor (BAFF-R) and signaling nuclear factor-kappaB (NF-κB) by A20 bindings to inhibit the activation of autoreactive B cells. Just like other antimonoclonal therapies, BAFF and the A20 enzyme can be used as therapeutic targets with a single use or combined with the standard therapy in patients with SLE. In addition, the use of BAFF and A20 also shown to have safe side effects in patients with SLE. CONCLUSION: BAFF protein and A20 enzyme present promising therapeutic targets for managing autoimmune diseases like SLE. Therapeutic interventions can be administered individually or in conjunction with standard treatments.  KEYWORDS: systemic lupus erythematosus, therapeutic targets, BAFF, A20
Co-Authors A Tjandrawati A Tjandrawati A, Muhammad Naufal Achadiyani Achadiyani Achadiyani Adhi Pribadi Afifah, Nadya Nurul Aini, Y H Aini, Yulia Hayatul Alfarish, M Arzan Alfi, Mohammad Abyan Amaylia Oehadian Andiyang R. Diredja Andri Reza Rahmadi Anjalia, Safira Anna Ariane Anna Ariane Anna Tjandrawati Artarini, Aluicia A. Astuti, Intan Widya Aulia Nurlatifah Awalia Awalia Azzahra, Fadhilla Zakya Bambang Setiyohadi Bambang Setiyohadi Bernard Santoso Suryajaya Bethy Suryawathy Hernowo Budi Setiabudiawan Chin Annsha Veimern Coriejati Rita D Nilasari D, H Purbo Dewi Kartika Turbawaty Dewi, Sumartini Dwi Budi Darmawati E Sutedja Edhyana Sahiratmadja Edhyana Sahiratmadja Eka Kurniawan Ellyana Sungkar Endang Sutedja Enrica, M Erica Kwan Yue Fadillah, Viki Faisal Parlindungan Faisal Parlindungan Fajar, Desi Reski Faliq, Muhammad Faza Farid Yudoyono Febyani, M Ferdy Ferdian Gede Kambayana Ghassani, Nadia Gita Guntur Darmawan Guntur Darmawan H Purbo D Habib Burahman Handono Halim Handono Kalim Harry Isbagio Harry Isbagio Hartati Purbo Dharmadji Hartati Purbo Dharmadji Hartati Purbo Dharmadji, Hartati Purbo I Nyoman Suarjana Ignatius Irawan Hidayat Ika Agus Rini Ika Vemilia Warlisti Indrawijaya, Yen YA. Irsan Hasan Ismiana Fatimah Modjaningrat Iwo, Maria I. Kasjmir, Yoga I Kennardi, Gabriel Bagus Lestari, Frida Dwi Lisda Amalia M Arzan Alfarish M Enrica M Febyani Maharani, Khalista Ismaya Malikul Chair Melisa I. Barliana Melisa Intan Barliana Modjaningrat, Ismiana Fatimah Mohammad Ghozali Mohammad Ghozali, Mohammad Muhammad Syawal Pratama Muhammad Zafrullah Arifin Mulya Nurmansyah Ardisasmita N Suraya Nadia Gita Ghassani Nadia Gita Ghassani Nadifa, Safira Najirman Najirman Nilasari, D Nita Novita Nita Novita Nur Atik Nur Atik O Suwarsa Ong, Paulus Anam Pande Ketut Kurniari Patrick Philo Paulus Anam Ong Permatasari, Lany Indah Praptama, Suhendra Pratama, Mirza Zaka Pratama, Muhammad Kevin Pratama, Muhammad Syawal Putra, Septian Dwi Putri Vidyaniati Putri, Rahmania Devina Rachmat Gunadi Wachjudi Rachmayati, S Radiyati Umi Partan Rahadian Nugi Sutrisno Rakhma Yanti Hellmi Rakhma Yanti Helmi Ria Bandiara Riardi Pramudiyo Rizky Abdullah RM Suryo Anggoro Rudy Hidayat Rully Hanafi Dahlan Ryan Ardian Saputro S Rachmayati Safira Anjalia Safira Nadifa Santi Andayani Sasfia Candrianita Sasfia Candrianita Septian Dwi Putra Setyorini Irianti Sevline Esthetia Ompusunggu Sevline Esthetia Ompusunggu Shadrina, Siti Azyyati Nur Soeseno Hadi Soeseno Hadi Stefanie Yuliana Usman Stefanie Yuliana Usman Stefanie Yuliana Usman Suhendra Praptama Sulaiman, Aina Zakia Sumariyono Sumartini Dewi Sumartini Dewi Suraya, N Surya Darma Suryana, Bagus Putu Putra Sutedja, E Sutrisno, Rahadian Nugi Suwarsa, O Tear, Alveron Andreas Tina Rostinawati Tjandrawati, A Trinugroho Heri Fadjari, Trinugroho Heri Usman, Stefanie Yuliana Valentine Natasya Moenadi Veimern, Chin Annsha Wahono, Cesarius Singgih Wijaya, Indra Wulansari Manuaba, Ida Ayu Ratih Y H Aini Yoga I Kasjmir Yue, Erica Kwan Yulia Hayatul Aini Yulyani Werdiningsih